Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11346006 | PMC |
Publication Analysis
Top Keywords
Similar Publications
[Therapeutic advances in metabolic dysfunction-associated steatotic liver disease].
Rev Med Suisse
August 2025
Service de gastroentérologie et d'hépatologie, Département de médecine, Hôpitaux universitaires de Genève, 1211 Genève 14.
The treatment of metabolic dysfunction-associated steatotic liver disease involves physical activity, weight loss, and management of comorbidities (diabetes, hypertension, dyslipidemia). In 2024, the American Food and Drug Administration provisionally approved resmetirom for metabolic dysfunction-associated steatohepatitis. Other promising molecules are being evaluated (glucagon-like peptide 1 receptor agonists, fibroblast growth factor 21 agonist).
View Article and Find Full Text PDFDefining non-invasive criteria for indicating drug therapy in metabolic-associated steatotic liver disease in clinical practice.
Clin Gastroenterol Hepatol
September 2025
CIBERehd, Spain; SeLiver group, Instituto de Biomedicina de Sevilla; Hospital Universitario Virgen del Rocío; Universidad de Sevilla. Electronic address:
Background: &Aim:Resmetirom is the first FDA-approved drug for metabolic-associated liver disease(MASLD) in F2-F3 patients with steatohepatitis. Non-invasive criteria have been proposed for initiating treatment; however, these have not been validated in clinical practice. We validated the proposed criteria and established new guidelines for initiating resmetirom treatment in clinical practice.
View Article and Find Full Text PDFImpact of Levothyroxine on Progression to and Complications of Cirrhosis in MASH.
Dig Dis Sci
August 2025
Digestive Disease Research Center, Medical University of South Carolina, Charleston, SC, USA.
Purpose: Resmetirom, a liver-targeted thyroid hormone receptor-β (THR-β) agonist, used to treat MASH, shares a similar mechanism of action with levothyroxine, a nonselective (THR-α/β) receptor agonist used to treat hypothyroidism. Given the potential effect of levothyroxine on THR-β, we hypothesized that it may have beneficial effects in MASH patients.
Methods: We used TriNetX to examine patients aged ≥ 18 years with MASH treated with levothyroxine from 1/1/16 to 1/1/25.
Resmetirom in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis.
Life (Basel)
August 2025
Department of Gastroenterology and Hepatology, Mayo Clinic, Phoenix, AZ 85259, USA.
Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), are among the most prevalent causes of chronic liver disease worldwide, closely linked to the global rise in overweight and obesity, type 2 diabetes, and metabolic syndrome. Until recently, treatment options were limited to lifestyle interventions, with no approved pharmacologic therapies. Resmetirom, a liver-directed, selective thyroid hormone receptor beta (THR-β) agonist, is a promising disease-modifying agent that targets hepatic lipid metabolism, inflammation, and fibrosis.
View Article and Find Full Text PDFScreening for MASLD and Advanced Fibrosis Among Patients With Obesity: A Cost-Effectiveness Analysis.
Obesity (Silver Spring)
August 2025
Department of Health Policy and Management, Tulane School of Public Health and Tropical Medicine, New Orleans, Louisiana, USA.
Objective: The study aimed to compare the cost-effectiveness of various strategies for screening for MASLD-related advanced hepatic fibrosis (fibrosis stage > 2) using the fibrosis-4 index (FIB-4) and liver stiffness measurement (LSM) by transient elastography (TE) in persons with obesity.
Methods: We created a decision-analytic model comparing three screening strategies: no screening, TE, and FIB-4 followed by TE. We used a Markov transition model to track liver state, with prevalence and transition probabilities specific to the population with obesity.